CVS director Larry Robbins dumps $317M, ARM insiders cluster-sell, Garden adds $2M more at FBIN

Today's window (May 22 13:39 UTC → May 23 13:00 UTC−5, ~23.5 hours) produced 48 new disclosures: 16 institutional filings (13D/G) and 32 Form 4 insider trades. The headline is clear — a $317M single-insider sale at CVS Health, now triple-source verified, towers over everything else while AI/semiconductor executives kept selling across five names and a pair of activist situations sharpened.

This is the largest single-insider Form 4 filing in the current window by a wide margin, and it passed multiple verification filters before being confirmed.

Larry Robbins — a CVS Health director and founder of hedge fund Glenview Capital Management (which manages approximately $7 billion in assets) — sold approximately 3.75 million CVS shares plus 378,000 cash-settled equity swaps between May 19 and May 21, totaling roughly $317 million 1 2. The sale cut his reported position by 43.73%. CVS had risen +21.64% in the month prior.

The specific transaction breakdown from SEC EDGAR confirms: May 19 (1,983,387 + 151 shares), May 20 (797,628 + 152,691 + 66,881 + 800 shares), May 21 (370,462 shares + 378,000 cash-settled swaps) 1. The transactions span three trading days — not a pre-arranged 10b5-1 plan based on available filings — which means this appears to be discretionary selling.

Robbins does not hold a C-suite operating role at CVS; as a board director, his view of the company is strategic rather than operational. A $317M sale representing nearly 44% of his position is a notable reduction by any measure. CVS is trading at roughly 14x forward earnings after recent healthcare-sector pressure, so the context is a stock that has recovered but remains well below its 2022 peaks. Whether Robbins is rotating proceeds, reducing Glenview's CVS concentration, or signaling a view on CVS's pharmacy benefit management headwinds isn't discernible from the filing alone.

ARM Holdings (ARM), the UK-based semiconductor IP company whose chip designs power most of the world's smartphones and an increasing share of AI inference hardware, saw two senior executives file Form 4 sales on the same day 2.

The Chief Legal Officer sold all 40,941 directly-held shares at $215.00 per share — a complete exit of direct holdings totaling $8.8 million. The Chief Commercial Officer sold 15,956 shares at $234.64 per share, cutting his position by 29.42% for proceeds of $3.74 million. Together the two transactions add $12.5M to ARM's insider selling total. ARM had risen +46.29% over the prior 30 days before these sales filed.

This is the continuation of a broader cluster: ARM recorded eight insider sales across five individuals over the past 30 days 2. The prior day's report covered MPWR CEO's $59.3M sale, the ALAB cluster at $74M+, and CoreWeave's $13.6M seven-person sell. Adding this window's ARM CLO and CCO sales, plus ASE Technology's $13.19M (see below) and Kulicke & Soffa's $2M, the AI/semiconductor insider selling tally reaches roughly $126M across the past ~48 hours — spanning chip IP (ARM), semiconductor packaging and testing (ASX), semiconductor equipment (KLIC), AI cloud GPU infrastructure (CRWV), laser semiconductors (LASR), and power management ICs (MPWR).

A CLO completely exiting direct holdings is less common than a C-suite executive trimming a planned tranche. The combination of a 100% direct-holding exit by the CLO and a near-third reduction by the CCO — both on the same filing date — is the most visible signal in ARM's recent insider data.

Fortune Brands Innovations (FBIN) — the home and security products company behind brands including Master Lock, Fiberon, and Moen — has been one of the harder-hit consumer discretionary names in 2026. The stock is down roughly 35.53% over the past three months and was sitting near its 52-week low on May 22.

Director Edward Garden bought an additional 57,400 shares at $34.89 on May 22 for $2.0 million 2, following his $13.66 million purchase on May 21 that was covered in yesterday's report. His two-day total now stands at approximately $15.66 million. Both purchases appear discretionary — no 10b5-1 plan is mentioned in available filings.

Garden controls these shares through entities GI SPV II L.P. and Green 73 LLC. His combined two-day position increase is +1.61% of the post-trade total, and he is buying at or near the 52-week intraday low of approximately $32.34. The pattern — a director making repeated large open-market purchases near a multi-month low — is the type of inside signal retail traders track because it represents skin-in-the-game conviction rather than a vesting-related compensation event.

Al Shams Investments LTD (a Bermuda corporation controlled by Wafic Rida Said, a Canadian citizen) filed Schedule 13D/A Amendment No. 7 on Braemar Hotels & Resorts (BHR), a Dallas-based hotel REIT, on May 22 3. The filing discloses 6,513,000 shares, representing 9.55% of outstanding.

The operative language in Item 4 of the filing states: "On May 20, 2026, in connection with the Reporting Persons' intent to seek to elect new directors at the Issuer's 2026 Annual Meeting of Stockholders, legal counsel to the Reporting Persons sent a letter..." requesting the company's standard director nomination questionnaire 3. That formal questionnaire request is the procedural step that precedes submitting a slate of director nominees under the company's bylaws.

Hub Cyber Security (HUBC), an Israeli cybersecurity company, received four separate Schedule 13G/A filings from individual investors within three trading days 4 5:

All four filers certified passive intent under Rule 13d-1(c) — each stated the shares "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer" 4. None of the four filings references the others, and no joint group filing has been submitted.

Four independent individuals filing passive disclosures on the same micro-cap Israeli cybersecurity company within 72 hours — collectively covering more than half the outstanding shares — is an unusual pattern. Porcello's filing uses CUSIP M6000J184 while Gnegy uses M6000J200, which may indicate different share classes or a data discrepancy. Whether this concentration reflects a private placement, a coordinated restructuring setup, or genuinely unrelated passive accumulation is not determinable from current filings. This warrants monitoring for a 13D conversion or an 8-K material event disclosure.

Casdin Capital LLC — a New York-based investment adviser focused on life sciences and healthcare technology — filed Schedule 13D/A Amendment No. 7 on BioLife Solutions (BLFS), a biotech cell-therapy tools company based in Bothell, WA 6. The filing reports 4,757,165 shares, 9.7% based on 48,857,415 shares outstanding as of April 30.

Casdin's Item 4 language states that the firm "has been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value" 6. This is the standard language for a holder that has converted from passive (13G) to active (13D) without yet announcing specific demands. On May 20, Casdin separately disclosed a $21.5M dip-buy in WGS (GeneDx Holdings), signaling continued biotech sector conviction.

Cynosure Group LLC, a Utah-based investment adviser, filed an initial Schedule 13D on Black Rock Coffee Bar (BRCB), a Scottsdale, AZ-based coffee chain, disclosing a 52.6% controlling stake 7. On May 15, Cynosure Partners III LP paid $72,973,697.44 for 12,042,712 LLC Units plus 1,600,000 Class A shares, simultaneously paying off a JPMorgan margin loan that had held the securities as collateral. The purchase triggered a conversion from passive 13G to active 13D status because Cynosure acquired more than 2% of outstanding shares within a 12-month window.

Governance rights secured with the transaction include: designation of Andrew Braithwaite (Cynosure Managing Director) as a board director, a board observer seat, and veto rights over board size expansion above nine members, net leverage above 2.0x, CEO termination, and director compensation changes — all conditioned on maintaining at least 7.5% ownership.

Bob R. Simpson — co-founder of XTO Energy, which ExxonMobil acquired in 2010 for $41 billion — filed Schedule 13D/A Amendment No. 1 on TXO Partners, L.P. (TXO), an oil and gas MLP based in Fort Worth, TX 8. Between May 7 and May 20, Simpson bought 1.2 million common units in open-market transactions using personal funds, at an aggregate cost of approximately $15.3 million. His total stake is now 7,950,000 units, representing 14.3% of the 55,446,407 units outstanding.

Simpson's address on the filing is c/o TXO Partners itself — a co-founder of one of the US's largest-ever E&P transactions buying open-market units in a small E&P MLP at what amounts to a sub-$13 average is a high-conviction insider accumulation signal in the energy sector.

FBNC watch: A director selling more than half his position in a regional bank is an unusual signal — FBNC is up roughly 8% year-to-date, making this less of a distress sale and more of deliberate profit-taking or concentration reduction. Worth monitoring for additional director activity.

WW cluster: Two separate WW International directors buying on the same date after a 56% three-month drawdown is one of the stronger "multiple insiders buying simultaneously" signals in this window, even if the total dollar size is modest.